News

The U.S. Food and Drug Administration (FDA) has approved ReAlta Life Sciences’ request to launch a Phase 2 clinical trial testing its experimental anti-inflammatory therapy RLS-0071 in people with chronic obstructive pulmonary disease (COPD) who are experiencing disease exacerbations. Exacerbations, or disease flare-ups, may occur several times per year…

From a Lace Up for Lungs challenge to learning about the impact of chronic obstructive pulmonary disease (COPD) in individual U.S. states, supporters are poised to participate in COPD Awareness Month, observed each November. World COPD Awareness Day is Nov. 15. Each fall, the COPD Foundation and the…

Ensifentrine, an investigational medication under review in the U.S. for chronic obstructive pulmonary disease (COPD), is effective across key patient subgroups, including when patients are separated by their history of lung exacerbations and type of background therapy. That’s according to recent pooled analyses from the ENHANCE-1 (NCT04535986) and…

The bacterium Stenotrophomonas maltophilia in the lungs is significantly associated with a higher risk of death and hospitalization due to disease exacerbation in people with chronic obstructive pulmonary disease (COPD), a study shows. Researchers are calling for clinical trials to test whether targeting S. maltophilia with antibiotics might improve outcomes…

After hospitalization due to chronic obstructive pulmonary disease (COPD) exacerbation, patients who live in rural areas and/or have to drive long distances to get to lung specialty centers are more likely to be prescribed an inhaler therapy regimen that isn’t in line with medical guidelines. That’s according to a…

In the U.S., many people with diagnosed or probable chronic obstructive pulmonary disease (COPD) at higher risk of disease exacerbations are not receiving recommended care, a new study found. “This analysis reveals the gaps and opportunities for improvement in the identification and management of patients with COPD in the…

Increases in new onset or recurring depression were seen among older Canadian adults with chronic obstructive pulmonary disease (COPD) during the early stages of the COVID-19 pandemic, a study shows. One in six patients without a history of depression before the pandemic developed it early on in it. For…

The U.S. Food and Drug Administration (FDA) has agreed to review Verona Pharma’s application seeking approval of inhaled ensifentrine as a maintenance treatment for chronic obstructive pulmonary disease (COPD). FDA’s review team now has up to 10 months to examine all data filed with the new drug…

Lupin Pharmaceuticals has penned a deal with low-cost pharmacy Mark Cuban Cost Plus Drugs and the COPD Foundation to broaden access for patients in the U.S. to a generic option of an approved tiotropium bromide dry inhalation powder for chronic obstructive pulmonary disease (COPD). Used with the…

Tiotropium bromide dry inhalation powder for use with the LupinHaler device, a generic version of Spiriva HandiHaler, is now available in the U.S. as a maintenance treatment of chronic obstructive pulmonary disease (COPD), Lupin Pharmaceuticals announced. Generics are considered bioequivalent to their brand-name alternatives,…